RG 7795

Drug Profile

RG 7795

Alternative Names: ANA 773; RG7795

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anadys Pharmaceuticals
  • Developer Anadys Pharmaceuticals; Roche
  • Class Antineoplastics; Antivirals; Small molecules
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B; Hepatitis C; Solid tumours

Most Recent Events

  • 01 Jul 2015 Phase-II clinical trials in Hepatitis B in Switzerland (PO)
  • 02 Feb 2012 Phase-I clinical trials in Hepatitis C in Netherlands (PO)
  • 02 Feb 2012 Anadys Pharmaceuticals terminates a phase IIa trial in Hepatitis C in Netherlands (ANA773-602; EudraCT2011-000728-14)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top